Comparative Pharmacology
Head-to-head clinical analysis: GLYCEROL PHENYLBUTYRATE versus PHEBURANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLYCEROL PHENYLBUTYRATE versus PHEBURANE.
GLYCEROL PHENYLBUTYRATE vs PHEBURANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glycerol phenylbutyrate is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This compound is excreted by the kidneys, providing an alternative pathway for waste nitrogen excretion in patients with urea cycle disorders.
Pheburane (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This alternative pathway for nitrogen excretion reduces ammonia levels in patients with urea cycle disorders.
450-600 mg/m2/day orally in three divided doses, rounded to the nearest 100 mg; maximum 20 g/day.
Adults: 1 gram orally twice daily, increased as tolerated to 2 grams orally twice daily. Maximum dose: 20 grams per day.
None Documented
None Documented
Clinical Note
moderateGlycerol phenylbutyrate + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Glycerol phenylbutyrate."
Clinical Note
moderateGlycerol phenylbutyrate + Atorvastatin
"The risk or severity of adverse effects can be increased when Glycerol phenylbutyrate is combined with Atorvastatin."
Clinical Note
moderatePrednisolone + Glycerol phenylbutyrate
"The therapeutic efficacy of Glycerol phenylbutyrate can be decreased when used in combination with Prednisolone."
Clinical Note
moderate0.8–1 hours (glycerol phenylbutyrate); 1.2–1.5 hours (phenylacetate); clinical context: short half-life requires thrice-daily dosing
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged (up to 4-6 hours), necessitating dose adjustment.
Renal: >90% as phenylbutyrate metabolites (mainly phenylacetylglutamine) within 24 hours; fecal: <1%
Primarily renal excretion. Approximately 50-80% of a dose is excreted unchanged in urine via glomerular filtration and tubular secretion. Biliary/fecal elimination is minimal (<5%).
Category C
Category C
Ammonia Detoxicant
Ammonia Detoxicant
Dexamethasone + Glycerol phenylbutyrate
"The therapeutic efficacy of Glycerol phenylbutyrate can be decreased when used in combination with Dexamethasone."